Tesamorelin
TH9507
Each vial contains 10 mg of Tesamorelin.
Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone. What the trial programme enrolled and measured, and what regulators have done with it, is set out under How it works below.
- Lyophilized powder, requires reconstitution
Price
$90.00 CAD
In stock
Produced & shipped in Canada
Specification
- CAS number
- 218949-48-5
- Molecular formula
- C221H366N72O67S
- Molecular weight
- 5,135.9 g/mol
- Purity
- ≥ 98.5% by RP-HPLC
- Form
- Lyophilized powder
- Third-party assay
- Purity, fill and endotoxin
- Origin
- Canada
- Storage
- -20 °C, protected from light
- Lot
- NVE-2409-A
How it works
Few compounds here have a completed phase 3 programme behind them, and this one does. What that programme enrolled, what it measured, and what came out of it are the three things worth knowing before reading any of it.
GHRH receptor
Where a GHRH analogue acts
The pituitary receptor the parent hormone acts at. The literature describes the analogue as acting there and takes pituitary growth-hormone release as the proximate question; that is pharmacology, not a finding about a person.
HIV-associated lipodystrophy
Who the pivotal trials enrolled
The phase 3 programme enrolled people with HIV-associated lipodystrophy. That is who was studied, and the reason evidence about anybody else is thin — a trial population is part of the finding rather than a detail around it.
Visceral adipose tissue by CT
The primary endpoint
Visceral adipose tissue, measured by computed tomography, was the primary endpoint of those trials. An endpoint is what a trial measured in the population it enrolled; it is not an outcome this vial carries.
Liver fat
Later academic work
Later academic studies in that same population examined liver fat. That work sits alongside the pivotal programme rather than extending it to anybody outside it.
Egrifta
The approved medicine, not this vial
A finished, manufactured, inspected and prescribed product exists under that name, on the strength of the programme above, in the jurisdictions that reviewed it. What a regulator approved is that product; nothing about it extends to material sold for laboratory use.
Where the evidence stands
Phase 3, published, and reviewed by two regulators — and confined to the one population those trials enrolled, outside which the evidence is thin. Approved elsewhere as Egrifta, a prescription medicine. Material on this page is research material, not that product.
Laboratory results
Opened as the laboratory issued them, unedited. Every certificate we publish
Research use only
Supplied as a laboratory research chemical. Not a drug, food or cosmetic, and not for human or veterinary use. No application guidance is provided or implied.
